Scoop: Tur­ing is con­sid­er­ing a $100M cash of­fer for the drug that trig­gered a na­tion­al scan­dal over drug pric­ing

Tur­ing Phar­ma­ceu­ti­cals has re­ceived a $100 mil­lion of­fer for the drug that trig­gered a na­tion­al up­roar over drug price goug­ing, End­points News has learned.

Eliseo Sali­nas

The com­pa­ny, launched by Mar­tin Shkre­li be­fore he be­came a light­ning rod in the con­tro­ver­sy over ex­treme drug pric­ing, was sup­posed to gath­er votes to­day on pro­posed mem­bers of the board at Tur­ing. That vote was sched­uled af­ter re­search chief Eliseo Sali­nas took over re­cent­ly as in­ter­im CEO as var­i­ous fac­tions fought for con­trol of the com­pa­ny.

In­stead of a board vote, though, Sali­nas dis­trib­uted a let­ter to share­hold­ers to­day say­ing that the vote would be post­poned as the com­pa­ny con­sid­ers an of­fer of $100 mil­lion in cash for Dara­prim from an un­named third par­ty.

One of the in­di­vid­u­als in­volved in the vote sent a copy of the let­ter to End­points News, which has been cov­er­ing this sto­ry from the be­gin­ning.

The bid­der “has con­duct­ed sig­nif­i­cant due dili­gence on Dara­prim un­der a Con­fi­den­tial­i­ty Agree­ment, and is com­mit­ted to clos­ing the trans­ac­tion with­in 30 days of ac­cep­tance of the of­fer, sub­ject to a pos­si­ble de­lay for Hart-Scott-Rodi­no fil­ing or oth­er le­gal or reg­u­la­to­ry re­views,” the let­ter states.

The let­ter goes on to say that the of­fer ar­rived last Fri­day and is be­ing re­viewed for fair­ness. That re­view is ex­pect­ed by the end of May. It goes on to add that the com­pa­ny has been con­sid­er­ing a sale, merg­er or new cap­i­tal in­fu­sion for the past year, af­ter the con­tro­ver­sy over Shkre­li’s de­ci­sion to jack up the price of Dara­prim by more than 5000% erupt­ed in­to con­tro­ver­sy.

Tur­ing is a pri­vate com­pa­ny and has nev­er re­vealed ex­act­ly what it’s been mak­ing on Dara­prim af­ter buy­ing it from Im­pax for $55 mil­lion, hik­ing the price of the old drug from $13.50 to $750 a tablet.

The com­pa­ny con­firmed the talks late Tues­day and is­sued this state­ment:

“In keep­ing with stan­dard cor­po­rate prac­tice, Tur­ing’s Board is ful­fill­ing its fidu­cia­ry oblig­a­tion to eval­u­ate a cred­i­ble of­fer for DARA­PRIM that was re­cent­ly re­ceived from a rep­utable phar­ma­ceu­ti­cal en­ti­ty. Due to con­fi­den­tial­i­ty re­stric­tions, we can­not dis­close in­for­ma­tion about the of­fer­or. Tur­ing con­tin­ues to fo­cus on de­vel­op­ment and com­mer­cial­iza­tion of in­no­v­a­tive treat­ments for se­ri­ous dis­eases and con­di­tions across a broad range of ther­a­peu­tic ar­eas.”

Shkre­li, who first of­fered to re­duce the price, in­stead scam­pered away, taunt­ing crit­ics and claim­ing that his move was just small time when com­pared to Big Phar­ma’s an­nu­al price hikes. He is now fac­ing a tri­al on un­re­lat­ed fed­er­al fraud charges next month in a Man­hat­tan court­room.

Mar­tin Shkre­li, for­mer chief ex­ec­u­tive of­fi­cer for Tur­ing Phar­ma­ceu­ti­cals AG, left, ar­rives at Fed­er­al Court with his at­tor­ney Ben­jamin Braf­man on Ju­ly 14, 2016 Bloomberg/Get­ty

Shkre­li’s tri­al is slat­ed to be­gin June 26, 5 days af­ter the CEO sched­uled a new board vote.

If the sale goes through, the let­ter con­tin­ues, in­vestors will be in line for $11 to $13 a share, once enough cash is set aside for le­gal and oth­er con­tin­gen­cies. The com­pa­ny will con­tin­ue to work in R&D, ac­cord­ing to the CEO.

Sali­nas took over the com­pa­ny re­cent­ly af­ter serv­ing as re­search chief. He re­placed long­time Shkre­li as­so­ciate Ron Tilles, who was left in charge af­ter Shkre­li re­signed short­ly af­ter his ar­rest. That switchup re­cent­ly trig­gered a fight over the board seats and con­trol of Tur­ing, start­ing a fight that has yet to be re­solved.

UP­DAT­ED: Roche bags 'break­through' an­ti-fi­bro­sis drug in $1.4B biotech buy­out deal

Roche is snapping up a “breakthrough” anti-fibrotic drug in a $1.4 billion buyout.

The pharma giant announced Friday that it is acquiring Promedior, primarily to get its hands on PRM-151, a recombinant form of human pentraxin-2 (PTX-2) protein that has nailed down mid-stage clinical data on idiopathic pulmonary fibrosis and demonstrating its potential for a range of fibrotic conditions.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

(Image: Associated Press)

Amarin emerges from an ex­pert pan­el re­view with a clear en­dorse­ment for Vas­cepa and high odds of suc­cess when the FDA weighs in for­mal­ly

Several FDA experts who gathered Thursday to consider the landmark approval of Vascepa to reduce cardio events in an at-risk population voiced their unease about various aspects of the efficacy and safety data, or ultimately the population it should be used to treat. But the overwhelming belief that the data pointed to the drug’s benefit and clearly outweighed risks carried the day for Amarin.

The panel voted unanimously (16 to 0) to support the company’s positive data presentation — backing an OK for expanding the label to include reducing cardio risk. The vote points Amarin $AMRN down a short path to a formal decision by the FDA, with the odds heavily in its favor. Chances are the rest of the questions about the future of this drug will be hashed out in the label’s small print.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

Federal Trade Commission commissioner Rohit Chopra testifies on Capitol Hill (AP Photo/Susan Walsh)

FTC clears Bris­tol-My­ers’ $74B deal to buy Cel­gene — but Dems sig­nal a po­ten­tial hard shift against Big Phar­ma M&A

Bristol-Myers Squibb’s record $74 billion takeover of Celgene is a done deal. And it will all be over — except for the lingering complaints from die-hard Celgene investors — on Wednesday.

Like much else that’s going on in Washington these days, the vote among the 5 FTC commissioners split along party lines, with the 3 Republicans voting to clear the way and the 2 Democrats steamed over what they see as a major M&A move that will lessen competition and innovation. And that split has big implications for the M&A side of the business if the Dems take the White House in 2020.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis spin­out’s first an­ti-ag­ing PhI­II is a flop, so now they’ll turn to Parkin­son’s chal­lenge as shares wilt

Novartis spinout resTORbio is grappling with the collapse of its lead clinical program this morning — an anti-aging R&D failure that will badly damage their rep in the field.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

BeiGene CEO John Oyler at an Endpoints event in Shanghai, October 2018 (Credit: Endpoints News/PharmCube)

UP­DAT­ED: In a first, FDA green-lights use of a Chi­nese built can­cer ther­a­py — and more are com­ing

Weeks after Amgen took a $2.7 billion stake in BeiGene, the Beijing-based biotech has secured its first-ever FDA approval for zanubrutinib, a BTK inhibitor, months ahead of schedule.

BeiGene’s drug, branded as Brukinsa, has secured accelerated approval for adult patients with mantle cell lymphoma (MCL) — a typically aggressive, rare, form of blood cancer — who have received at least one prior therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

What does $62B buy you these days? A lot, says Take­da ex­ecs as the phar­ma play­er promis­es a block­buster R&D fu­ture

First comes the $62 billion buyout. Then comes the asset auction and reorganization to pay down debt. Now comes the detailed pledge of a bigger, brighter future in drug development.

That’s where Takeda finds itself on R&D day today, about 11 months after closing on their Shire acquisition. R&D chief Andy Plump is joining CEO Christophe Weber and other top members of the team to outline a new set of priorities in the greatly expanded pipeline at Takeda, which has jumped into the top ranks of the world’s pharma giants in the wake of the Shire deal.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

GSK's asth­ma bi­o­log­ic Nu­cala scores in rare blood dis­or­der study

GlaxoSmithKline’s asthma drug Nucala, which received a resounding FDA rejection for use in chronic obstructive pulmonary disease (COPD) last year, has shown promise in a rare blood disorder.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck buys a fledg­ling neu­rode­gen­er­a­tive biotech spawned by an old GSK dis­cov­ery al­liance. What’s up with that?

Avalon Ventures chief Jay Lichter has a well-known yen for drug development programs picked up in academia. And what he found in Haoxing Xu’s lab at the University of Michigan pricked his interest enough to launch one of his umbrella biotechs in San Diego.

Xu’s work laid the foundation for Avalon to launch Calporta, which has been working on finding small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for lysosomal storage disorders. And that pathway, they believe, points to new approaches on major market neurodegenerative diseases like Parkinson’s, ALS and Alzheimer’s.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

(Image: Associated Press)

No­var­tis scores its lat­est FDA OK — this time for a new sick­le cell dis­ease drug picked up in a $665M deal

Novartis’ decision to buy Oklahoma-based biotech Selexys 3 years ago for up to $665 million has paid off with an FDA approval today.

Blessed with the FDA’s breakthrough drug designation for a speedy review, the pharma giant has pinned down an approval for crizanlizumab, a new therapy designed to reduce the frequency of painful incidents of vaso-occlusive crises among sickle cell disease patients 16 or older.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.